EAST WINDSOR, NJ -- (MARKET WIRE) -- August 09, 2006 -- NexMed, Inc. (NASDAQ: NEXM), a developer of innovative pharmaceutical products based on its NexACT® transdermal drug delivery technology, today announced its second quarter 2006 financial results. For the quarter ended June 30, 2006, the Company recorded revenue of $533,655 which was primarily attributable to the revenue recognized for the Novartis licensing agreement. For the quarter, the net loss applicable to common stock was $1,033,363 or $0.02 per share, as compared to $5,097,194 or $0.10 per share for the same period in 2005. The decrease in net loss applicable to common stock is primarily attributable to the increase in revenues and reduction in overhead.
